Pierre Armand Morgon

Currently, Pierre Armand Morgon is CEO at Mrgn Advisors since 2015, CEO at Drug Abuse Sciences since 2006, Chief Executive Officer & Manager at MRGN Advisors SARL, Chief Executive Officer at Ibex Therapeutics SA, Chairman at Kupando GmbH since 2021, Non-Executive Chairman at Adiposs SA since 2020, Chairman at MYCB1 Group BV since 2020, Chairman at MYCB1 BV since 2020, Chairman at Health Technology Holding Srl, Non-Executive Director at Univercells SA since 2018, Independent Non-Executive Director at Limula SA, Independent Non-Executive Director at Barinthus Biotherapeutics Plc since 2018, Director at International Association for Biologicals, Director at Zambon Biotech SA, and Advisor at CUBE Labs Srl.
Former roles include Chief Executive Officer at AJ Biologics Sdn.
Bhd.
from 2014 to 2016, Chairman at Virometix AG from 2017 to 2019, Chairman at Alma Biotherapeutics from 2017 to 2018, Marketing Director at Cegedim SA, Independent Director at Theradiag SA from 2012 to 2018, Independent Non-Executive Director at CanSino Biologics, Inc. from 2018 to 2019, Director at Schering-Plough SAS from 2006 to 2008, Non-Executive Director at Barinthus Biotherapeutics (UK) Ltd. from 2017 to 2021, Non-Executive Director at Eurocine Vaccines AB from 2013 to 2019, Director at Amoéba SA from 2020 to 2021, Chief Operating Officer at Valerio Therapeutics SA from 2008 to 2009, and VP-Franchise & Global Marketing Strategy at Sanofi Pasteur SA from 2009 to 2013.
Education includes undergraduate studies at INSEAD and International Institute for Management Development, an MBA from ESSEC Business School, a doctorate from the University of Lyon, and graduate studies at Jean Moulin University Law School.